Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer

Oncogene

Volumn 30, Issue 33, 2011, Pages 3570-3584

  Charoenfuprasert, S ^a,f   Yang, Y Y ^b   Lee, Y C ^b,g   Chao, K C ^c   Chu, P Y ^d   Lai, C R ^c   Hsu, K F ^e   Chang, K C ^e   Chen, Y C ^f   Chen, L T ^f   Chang, J Y ^f   Leu, S J ^a   Shih, N Y ^f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^g GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

CA125; malignant ascitic fluid; ovarian cancer; phage display; tumor associated antigen

Indexed keywords

CA 125 ANTIGEN; PEPTIDE LIBRARY; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE P60; PROTEIN P21; PROTEIN P27; SALT INDUCIBLE KINASE 3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADENOMYOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PEPTIDE ANALYSIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIGENS, NEOPLASM; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENES, SRC; HUMANS; MALE; MICE; OVARIAN NEOPLASMS; PROTEIN KINASES;

MUS;

EID: 80051787302     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.77     Document Type: Article

References (33)

1. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO et al. (2010). SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18: 109-121.
2. Amin N, Khan A, St Johnston D, Tomlinson I, Martin S, Brenman J et al. (2009). LKB1 regulates polarity remodeling and adherens junction formation in the Drosophila eye. Proc Natl Acad Sci USA 106: 8941-8946.
3. Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA et al. (2005). Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 14: 306-318. (Pubitemid 40270090)
4. Berdeaux R, Goebel N, Banaszynski L, Takemori H, Wandless T, Shelton GD et al. (2007). SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat Med 13: 597-603. (Pubitemid 46828484)
5. Brewer BG, Mitchell RA, Harandi A, Eaton JW. (2009). Embryonic vaccines against cancer: an early history. Exp Mol Pathol 86: 192-197.
6. Bright NJ, Thornton C, Carling D. (2009). The regulation and function of mammalian AMPK-related kinases. Acta Physiol (Oxf) 196: 15-26.
7. Cannistra SA. (2004). Cancer of the ovary. N Engl J Med 351: 2519-2529.
8. Cantley LC. (2002). The phosphoinositide 3-kinase pathway. Science 296: 1655-1657. (Pubitemid 34579158)
9. Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK et al. (2006). Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res 12: 5746-5754. (Pubitemid 44629605)
10. Cheng H, Liu P, Wang ZC, Zou L, Santiago S, Garbitt V et al. (2009). SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal 2: ra35.
11. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. (1995). Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
12. Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K et al. (2008). Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding auto-antibodies in ovarian cancer patients. Clin Cancer Res 14: 764-771. (Pubitemid 351231158)
13. Giancotti FR, Dorsett BH, Qian HN, Cronin WJ, Barber HR, Ioachim HL. (1990). Ovarian cancer-associated antibodies recovered from ascites: their use for the isolation of ovarian cancer-associated antigen to produce monoclonal antibodies. Gynecol Oncol 37: 24-28. (Pubitemid 20147964)
14. Guarino M. (2007). Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 39: 2153-2160. (Pubitemid 47484287)
15. Horike N, Takemori H, Katoh Y, Doi J, Min L, Asano T et al. (2003). Adipose-specific expression, phosphorylation of Ser794 in insulin receptor substrate-1, and activation in diabetic animals of salt-inducible kinase-2. J Biol Chem 278: 18440-18447. (Pubitemid 36799466)
16. Katoh Y, Takemori H, Horike N, Doi J, Muraoka M, Min L et al. (2004). Salt-inducible kinase (SIK) isoforms: their involvement in steroidogenesis and adipogenesis. Mol Cell Endocrinol 217: 109-112. (Pubitemid 38596635)
17. Katoh Y, Takemori H, Lin XZ, Tamura M, Muraoka M, Satoh T et al. (2006). Silencing the constitutive active transcription factor CREB by the LKB1-SIK signaling cascade. FEBS J 273: 2730-2748.
18. Kowanetz M, Lonn P, Vanlandewijck M, Kowanetz K, Heldin CH, Moustakas A. (2008). TGFbeta induces SIK to negatively regulate type I receptor kinase signaling. J Cell Biol 182: 655-662.
19. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J et al. (2010). Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst 102: 812-827.
20. Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J et al. (2004). LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. Embo J 23: 833-843. (Pubitemid 38418750)
21. Mizrachy-Schwartz S, Kravchenko-Balasha N, Ben-Bassat H, Klein S, Levitzki A. (2007). Optimization of energy-consuming pathways towards rapid growth in HPV-transformed cells. PLoS One 2: e628.
22. O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K. (2002). The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 23: 154-169. (Pubitemid 44858307)
23. Okamoto M, Takemori H, Katoh Y. (2004). Salt-inducible kinase in steroidogenesis and adipogenesis. Trends Endocrinol Metab 15: 21-26. (Pubitemid 38198095)
24. Old LJ. (2008). Cancer vaccines: an overview. Cancer Immun 8(Suppl 1): 1.
25. Paciga M, McCudden CR, Londos C, DiMattia GE, Wagner GF. (2003). Targeting of big stanniocalcin and its receptor to lipid storage droplets of ovarian steroidogenic cells. J Biol Chem 278: 49549-49554.
26. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. (2009). A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58: 1535-1544.
27. Rosenthal AN, Menon U, Jacobs IJ. (2006). Screening for ovarian cancer. Clin Obstet Gynecol 49: 433-447. (Pubitemid 44181417)
28. Ruda JM, Beus KS, Hollenbeak CS, Wilson RP, Stack Jr BC. (2006). The effect of single agent oral fusaric acid (FA) on the growth of subcutaneously xenografted SCC-1 cells in a nude mouse model. Invest New Drugs 24: 377-381. (Pubitemid 43876073)
29. Runnebaum IB, Stickeler E. (2001). Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 127: 73-79.
30. Screaton RA, Conkright MD, Katoh Y, Best JL, Canettieri G, Jeffries S et al. (2004). The CREB coactivator TORC2 functions as a calcium-and cAMP-sensitive coincidence detector. Cell 119: 61-74. (Pubitemid 39349320)
31. Serlachius M, Alitalo R, Olsen HS, Andersson LC. (2002). Expression of stanniocalcin-1 in megakaryocytes and platelets. Br J Haematol 119: 359-363. (Pubitemid 35365482)
32. Sjostrom M, Stenstrom K, Eneling K, Zwiller J, Katz AI, Takemori H et al. (2007). SIK1 is part of a cell sodium-sensing network that regulates active sodium transport through a calcium-dependent process. Proc Natl Acad Sci USA 104: 16922-16927. (Pubitemid 350210966)
33. Taylor DD, Gercel-Taylor C, Parker LP. (2009). Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 115: 112-120.